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Abstract
Background: Cysteine proteinases (CPs) from papaya (Carica papaya) possess anthelmintic properties against
human soil-transmitted helminths (STH, Ascaris lumbricoides, Trichuris trichiura and hookworm), but there is a lack of
supportive and up-to-date efficacy data. We therefore conducted two randomized controlled trials in pigs to assess
the efficacy of papaya CPs against experimental infections with T. suis.
Methods: First, we assessed efficacy by means of egg (ERR) and adult worm reduction rate (WRR) of a single-oral
dose of 450 μmol active CPs (CP450) against low (inoculum of 300 eggs) and high (inoculum of 3,000 eggs) intensity T.
suis infections and compared the efficacy with those obtained after a single-oral dose of 400 mg albendazole (ALB). In
the second trial, we determined and compared the efficacy of a series of CP doses (45 [CP45], 115 [CP115], 225 [CP225],
and 450 [CP450] μmol) against high intensity infections.
Results: CP450 was highly efficacious against both levels of infection intensity, resulting in ERR and WRR of more than
97%. For both levels of infection intensity, CP450 was significantly more efficacious compared to ALB by means of WRR
(low infection intensity: 99.0% vs. 39.0%; high infection intensity; 97.4% vs. 23.2%). When the efficacy was assessed by
ERR, a significant difference was only observed for high intensity infections, CP450 being more efficacious than ALB
(98.9% vs. 59.0%). For low infection intensities, there was no significant difference in ERR between CP450 (98.3%)
and ALB (64.4%). The efficacy of CPs increased as a function of increasing dose. When determined by ERR, the
efficacy ranged from 2.1% for CP45 to 99.2% for CP450. For WRR the results varied from −14.0% to 99.0%,
respectively. Pairwise comparison revealed a significant difference in ERR and WRR only between CP45 and
CP450, the latter being more efficacious.
Conclusions: A single dose of 450 μmol CPs provided greater efficacy against T. suis infections in pigs than a
single-oral dose of 400 mg ALB. Although these results highlight the possibility of papaya CPs for controlling human
STH, further development is needed in order to obtain and validate an oral formulation for human application.
Keywords: Trichuris, Papaya, Cysteine proteinases, Ethno-medicine, Soil-transmitted helminths, Egg reduction rate,
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Background
The London Declaration on Neglected Tropical Diseases
(NTD) brought an international awareness and commit-
ment to combat NTD that has since resulted worldwide
in increased pledges of drug donations [1]. However,
these worldwide prospects for more frequent mass drug
administration (MDA) campaigns warrant caution, par-
ticularly for soil-transmitted helminths (STH, Ascaris
lumbricoides, Trichuris trichiura and hookworms). First,
MDA programs to control STH predominantly rely on
just one group of anthelminthics, the benzimidazole
drugs (albendazole (ALB) and mebendazole (MEB)), which
make these campaigns highly vulnerable to the develop-
ment of anthelminthic resistance [2-5]. Second, these
benzimidazole drugs cannot be administered to women in
the first trimester of pregnancy due to their teratogenicity
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[6]. Thirdly, a single dose of the benzimidazole drugs
against the different STH is often not sufficient to clear
infections completely, showing primarily poor efficacy
against T. trichiura infections, especially when levels of
infection intensity are high [7-10]. Despite the pressing
and obvious need for alternative drugs, there are currently
no compounds available on the market that outcompete
the benzimidazoles in terms of efficacy, safety and
feasibility [11-15].
Studies going back many decades have indicated that the
cysteine proteinases (CPs) from papaya (Carica papaya),
collectively known as ‘papain’, have the ability to control
gastrointestinal parasites in humans, including STH
[16-18]. The CPs of papaya reside in the latex that is
present in most parts of the plant (but not the ripe
fruit) and is released upon injury. Plant derived CPs
are thought to help protect the developing and unripe
fruits from exploitation by plant-parasitic nematodes
and by arthropod pests [19-21]. It is known that there
are four CPs in the latex, of which papain is the least
abundant [22]. Confusingly, crude preparations of papaya
latex CPs are often referred to as ‘papain’, but we will use
the term ‘papaya CPs’. The anthelmintic application of pa-
paya CPs in public health subsequently received very little
attention, probably due to competition with the upcoming
synthetic anthelmintic drugs. However, it is already appar-
ent that papaya CPs are most likely safe and tolerable, as
they are already present in the human food chain (e.g.,
meat tenderizers, beer clarifiers, and enhancers of food
item flavours [23,24]. Second, papaya CPs with a molecu-
lar weight of ~23.5 kDa are very unlikely to be absorbed
without first being broken down to peptides, and hence
can probably be administered to women at an early stage
of pregnancy. In addition, papaya CPs have a different
mode of action to current anthelmintics (digestion of
helminth cuticles) [25], and hence they are a serious
contender for an alternative backup drug should anthel-
minthic resistance occur against the benzimidazoles.
They are likely to have more than one target site on the
cuticle, making rapid development of resistance very
unlikely. Finally, their impact is not restricted to STH,
but may have also a clear impact on other gastro-intestinal
parasites, as shown by the in vitro experiments on animal
tapeworms [25,26].
With increasing reports of resistance against current
synthetic anthelminthics in veterinary medicine and lack
of efficacy in some cases, the efficacy of papaya CPs has
mainly been evaluated against gastrointestinal nematodes
in sheep (Haemonchus contortus) [27] and also in various
in vivo laboratory models [28-32]. In the present study, we
evaluated the efficacy of papaya CPs against experimental
T. suis infections in pigs, the latter being an appropriate
and relevant animal model for human trichuriasis. This
host-parasite combination allows the assessment of efficacy
by means of reduction in both egg counts and adult worm
counts. In addition, we verified whether egg counts in stool
are an appropriate proxy for worm burden.
Methods
Trial design
Two randomized control efficacy trials were conducted.
In the first trial, we assessed how a single-oral dose of
450 μmol active papaya CPs compares with a single-oral
dose of 400 mg ALB (proof-of-principle trial) for low
and high intensity T. suis infections. In the second trial,
we determined to what extent we could reduce the dose
of papaya CPs without loss of the efficacy levels obtained
by administering 450 μmol papaya CP (dose–response
trial).
In each of these trials, Rattlerow Senghers hybrid piglets
between 8–12 weeks were infected with T. suis eggs
containing infectious larvae at day (D)-42. At D-1, levels
of egg excretion by means of fecal egg counts (FECs)
were determined, after which animals were randomized
to a treatment group stratifying for level of egg excretion.
The treatments were given on D0. By this time, the mean
body weight of the pigs was 43.3 kg (95% confidence inter-
val (95% CI): 40.2-46.2). Each treatment group included six
animals. Finally, at D + 6 FECs were determined again and
at D + 7 all the animals were sacrificed and the total num-
ber of adult T. suis was assessed. Although each of the two
trials followed this general format, they differed in the
number of T. suis (inoculum), the product and the dose of
the product administered. In the proof-of-principle trial,
we assessed the efficacy of a single-oral dose of 450 μmol
papaya CPs and a single-oral dose of 400 mg ALB against
low (inoculum= 300 embryonated T. suis eggs) and heavy
intensity T. suis infections (inoculum = 3,000 embryonated
T. suis eggs). In the dose–response trial, we assessed the ef-
ficacy of a single oral-dose of 45 (10% of the dose evaluated
in the proof-of-principle trial), 115 (25%), 225 (50%)
and 450 μmol (100%) of papaya CPs against high levels
of infection intensity (inoculum = 3,000T. suis eggs). The
Ethical Committee of the Faculty of Veterinary Medicine,
Ghent University (Belgium) approved the study protocol
of both trials (Trial 1: EC2011/171; Trial 2 EC2012/178).
The animals were bred, raised and housed at the Animal
Experimental Unit (Biocentrum Agrivet) of the Faculty of
Veterinary Medicine, Ghent University, Belgium.
Papaya cysteine proteinase and albendazole
A supernatant from papaya latex enriched in CP activity
was prepared as described [27]. Briefly, spray-dried C.
papaya latex (Enzymase P1, Enzymase International S.A.,
33 rue Jean-Baptiste BAECK - bte 3, B - 1190 Brussels,
Belgium) was suspended in water then centrifuged at
17,700 × g. The supernatant was taken and concentrated by
dialysis over polyethylene glycol 20,000. The concentrated
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material was aliquotted into individual containers and
freeze-dried. Sample aliquots were taken at various
time-points, weighed, and the concentration of active
CP was determined by active-site titration with the CP
inactivator E-64 (L-trans-epoxysuccinyl-leucylamido
4-guanidino butane – Sigma Aldrich) [33]. Once aliquotted
and freeze-dried, there was no detectable deterioration of
enzyme activity over a period of at least 2 years, the specific
activity of the material remaining at 10 μmol/g. The 400
mg ALB originated from GlaxoSmithKline Pharmaceuticals
Limited, India.
Inoculation of T. suis eggs
For each animal, the inoculum of 300 or 3,000 embryo-
nated T. suis eggs was suspended in 5 ml of tap water,
and subsequently administered directly into the stomach
of the animal by gavage. To avoid accumulation of the T.
suis eggs, the tube used to gavage was flushed with
10 ml of tap water before inoculating the next animal
in the infection sequence. The T. suis eggs were kindly
provided by Peter Nejsum and Stig Milan Thamsborg
(Department of Veterinary Disease Biology, Faculty of
Health and Medical Sciences, University of Copenhagen,
DK-1870 Frederiksberg C, Denmark).
Administration of papaya CPs and ALB
Both papaya CPs and ALB tablets were crushed to pow-
der using a pestle and mortar. Subsequently, the powder
was suspended in tap water. The volume in which the
papaya CPs was suspended ranged from 20 ml (45 μmol)
to 150 ml (450 μmol). One ALB tablet was suspended in
20 ml of tap water. Both papaya CPs and ALB were ad-
ministered directly into the stomach of the animal by
gavage. The control group received 30 ml of tap water
administered directly into the stomach by gavage. To
avoid accumulation of the products, the tube used to
gavage was flushed with 10 ml of tap water before
inoculating the following animal. In addition to this, a
separate tube was used for each treatment group to avoid
cross-contamination.
Parasitological examination
Assessment of FEC
FECs were determined using the McMaster egg counting
method based on a protocol described by the Ministry
of Agriculture, Fisheries, and Food (1986) [34]. Briefly,
four grams of stool were suspended in 60 ml of saturated
salt solution at room temperature (density ~ 1.2), prepared
by adding NaCl to 5 l of warm distilled water (40–50°C)
until no more salt went into solution and the excess set-
tled on the bottom of the container). The fecal suspension
was poured three times through a wire mesh (aperture of
250 μm) to remove large debris. Then, 0.5 ml aliquots
were added to each of the two chambers of a McMaster
slide (http://www.mcmaster.co.za). Both chambers were
examined under a light microscope using a 100x magnifi-
cation and the FECs, expressed as eggs per gram of stool
(EPG), were obtained by multiplying the total number of
eggs by 50.
Assessment of total adult T. suis worm counts
After sacrificing the animals, the large intestine (from
caecum to rectum) was removed from the abdominal
cavity. Then, the large intestine was opened longitudin-
ally and rinsed with water to remove the content. The
content of the intestine was further thoroughly washed
on wire mesh (aperture of 800 μm), withholding the
adult T. suis. Finally, adult T. suis worms were counted
both in situ in the mucosa of the large intestine and in
the contents of the intestine. To obtain the total adult
T. suis worm counts (WC), the number of adult worms
found in the mucosa of the large intestine was added to the
number of worms found in the content of the intestine.
Statistical analysis
Statistical analysis consisted of three parts. First, we veri-
fied whether animals were successfully randomized based
on FECs. To this end, arithmetic mean FEC at D-1 was
summarized for each of the different treatment groups in
the two trials (in the first trial this was done for each level
of infection intensity separately). Corresponding 95% con-
fidence intervals were determined by bootstrap analysis
(10,000 iterations). Differences in FECs at D-1 across the
treatment groups were evaluated by a permutation test
based on the F-statistic (10,000 iterations). Second, we
report the efficacy of the different treatment regimens
against T. suis infections in each trial by means of egg
reduction rate (ERR) at D + 6 and the adult T. suis worms
at D + 7 reduction rate (WRR) compared to the control
group using the formulae below:
ERR ¼ 100%
" 1− arithmetric mean of FECs at Dþ 6 in the treatment group
arithmetric of FECs at Dþ 6 in the control group
! "
WRR ¼ 100%
" 1‐ arithmetric mean of WCs at Dþ 7 in the treatment group
arithmetric mean of WCs at Dþ 7 in the control group
! "
Corresponding 95% confidence intervals were deter-
mined by bootstrap analysis (10,000 iterations). In the
proof-of-principle trial, differences in efficacy between
a single-oral dose of CPs and ALB were evaluated for
each of the two levels of infection intensity using a permu-
tation test based on the t-statistic (10,000 iterations). For
the dose–response trial, any difference in efficacy between
the four doses of CPs was evaluated, using a permutation
test based on the t-statistic (10,000 iterations). Tukey’s
method was applied for multiple comparisons. Third,
we evaluated whether FECs are an appropriate proxy for
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worm burden. To this end, we determined the correla-
tions between the WC at D+7 and the corresponding
FECs at D+6, for all animals in both trials by calculating
the Pearsons’ correlation coefficient. The statistical ana-
lysis was conducted in the statistical software R (version
3.0.1, 2013, The R Foundation for Statistical Computing
Platform). The level of significance for each test was set
at p ≤0.05.
Results
Proof-of-principle trial
Table 1 summarizes the number of animals, mean FECs
at D-1, the mean FECs at D+6 and the mean WCs at D+7
for each of the three treatment groups (single-oral dose of
450 μmol papaya CPs [CP450], single-oral dose of 400 mg
ALB, control), and the efficacy of CP450 and ALB for
low and high intensity T. suis infections, separately. One
animal in the CP450 group inoculated with 3,000 T. suis
eggs died during the trial. Autopsy did not reveal any
causal association between the CP450 treatment and
death. In the remaining groups, all 6 animals completed
the trial. The mean FECs at D-1 for animals inoculated
with 300 eggs, ranged from 8.3 EPG (95% CI: 0.0; 25.0)
in both the P450 and ALB group to 16.7 EPG (95% CI:
0.0; 50.0) in the control group. For animals inoculated
with 3,000 eggs, the mean FEC at D-1 ranged from
366.7 EPG (95% CI: 58.3; 800.0) in the control group to
483.3 (95% CI: 116.7; 916.7) in the ALB. For both levels
of infection intensity, there was no significant difference
in FEC at D-1 across the different treatment groups
(Flow = 0.17, p = 0.78, Fhigh = 0.08, p = 0.93). The mean
WC at D+7 in the control animals inoculated with 300
eggs was 131.5 (95% CI: 107.2; 161.3, recovery rate of
43.8% [95% CI: 35.7; 53.8]), for the control animals inoc-
ulated with 3,000 eggs the mean WC equaled 1,142.2
(95% CI: 893.0; 1,419.0, recovery of 38.1% [95% CI: 29.8;
47.3]). The ratio of mean FECs at D+6 and WCs at D+7
in the control animals inoculated with 3,000 eggs and
the control animals inoculated with 300 eggs was 18.6
[95% CI: 5.2; 57.0] and 8.7 [95% CI: 6.3; 11.8],
respectively.
A single-oral dose of P450 was highly efficacious,
resulting in a ERR and WRR of almost 100% for both
low (ERR: 98.3 [95% CI: 92.7; 100]; WRR: 99.0% [95%
CI: 97.7; 99.9]) and high intensity infections (ERR: 98.9
[95% CI: 95.5; 99.9]; WRR: 97.4%% [95% CI: 94.3; 99.7]).
A single-oral dose of ALB showed poor efficacy against
both levels of infection intensity (low infection intensity:
ERR: 64.4% [95% CI: −15.8; 96.3]; WRR: 39.0% [95% CI: 2.4;
69.1], high infection intensity: ERR: 59.0% [95% CI: −47.0;
83.4]; WRR: 23.2% [95% CI: −7.8; 49.7]). For both levels
of infection intensity, a single-oral dose of P450 was
significantly more efficacious compared to a single-oral
dose of ALB by means of WRR (tlow = 3.5, p = 0.003; thigh =
6.1, p = 0.005). When the efficacy was assessed by means
of ERR, a significant difference was only observed for high
levels of infection intensity, CP450 being more efficacious
than ALB (t = 3.5, p = 0.006). For low level infection in-
tensity, there was no significant difference in ERR between
CP450 and ALB (t = 1.71, p = 0.15).
Dose–response trial
Table 2 summarizes the number of animals, mean FEC
at D-1, the mean FEC D+6, and WC at D7 for each of
the five treatment groups (single-oral dose of 45, 115,
225 and 450 μmol CP [CP45, CP115, CP225 and
CP450] and control) against high-intensity T. suis in-
fections. All 30 animals (6 animals per treatment group)
completed the trial. The mean FEC at D-1 ranged from
233.3 EPG (95% CI: 16.7; 558.3) for the CP115 group to
500.0 EPG (95% CI: 41.7; 1,200.0) for the CP45 group.
There was no significant difference in FEC at D-1 across
the different treatment groups (F = 0.219, p = 0.95). The
mean WC at D+7 in the control animals was 856.3 (95%
CI: 328.7; 1,384.0, recovery rate of 28.5% [95% CI: 11.0;
46.1]).
Table 1 The efficacy of papaya CPs and albendazole against low and high intensity T. suis infections
n Mean FECs at D-1
(EPG) (95% CI)
Mean FECs at D+6
(EPG) (96% CI)
ERR (%)
(95% CI)
Mean WCs at
D7 (95% CI)
WRR (%)
(95% CI)
Low infection intensity (inoculum = 300 eggs)
CP450 6 8.3(0.0; 25.0) 8.3(0.0; 25.0) 98.3(92.7; 100) 1.3(0.2; 2.8) 99.0*(97.7; 99.9)
ALB 6 8.3(0.0; 25.0) 175.0(16.7; 358.3) 64.4(−15.8; 96.3) 80.2(40.8; 122.0) 39.0*(2.4; 69.1)
Control 6 16.7(0; 50.0) 491.7(183.3; 800.0) _ 131.5(107.2; 161.3) _
High infection intensity (inoculum = 3,000 eggs)
CP450 5** 420.0(60.0; 780.0) 100.0(10.0; 230.0) 98.9*(95.5; 99.9) 29.2(3.2; 63.2) 97.4*(94.3; 99.7)
ALB 6 483.3(116.7; 916.7) 3800.0(1908.3; 5666.7) 59.0*(−47.0; 83.4) 877.2(597.0; 1,094.3) 23.2*(−7.8; 49.7)
Control 6 366.7(58.3; 800.0) 9266.7(2683.3; 17416.7) _ 1142.2(893.0; 1,419.0) _
The fecal egg counts (FEC) at day (D) -1, mean worm counts (WC) at D+7 and the reduction in WC at D+7 compared to the control group (WCR).
*pair-wise comparison between CP450 and ALB revealed a significant difference with p-value <0.01; **One animal which received 3,000 eggs of T. suis and which
was assigned to the CP450 treatment died in the course of trial. Autopsy did not reveal any causal association between the treatment and death.
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Overall, the efficacy measured by ERR and WRR in-
creased as a function of increasing dose of CP. For
ERR, the results ranged from 2.1% (95% CI: −629.8;
68.9) for a single oral dose of CP45 to 99.2% (95% CI:
93.6; 100) for a single oral dose of CP450. For WRR
these results ranged from −14.0% (95% CI: −213.7; 36.1)
to 99.0% (95% CI: 97.0; 99.7), respectively. As illustrated in
Figure 1, there was initially a relatively small fall in efficacy
as the dose was reduced from CP450 to CP115, and then
a steep drop in efficacy towards CP45. A single-oral dose
CP450 was more efficacious compared to a single-oral
dose of CP45 by means of both ERR (t = 2.7, p = 0.005)
and WRR (t = 6.1, p = 0.001). The remaining pair-wise
comparisons did not reveal a significant difference in
efficacy (p >0.12).
FEC as a proxy for worm burden
Overall, there was high correlation (Rs = 0.80, p <0.0001)
between WC and FEC. However, as illustrated in Figure 2,
the relationship between these two variables was not lin-
ear, rather the FECs increased as an exponential function
of WCs (R2 = 0.83).
Discussion
In the present study we conducted two randomized
controlled efficacy trials to evaluate the efficacy of
papaya CPs against experimental T. suis infections in
pigs, and we clearly demonstrated that a single application
of CPs at the higher doses used for treatment is far more
effective than the most widely used synthetic anthelmintic.
Therefore, this study confirms that papaya CPs have
Table 2 The efficacy of four doses of papaya CPs against high intensity T. suis infections
Treatment arm n Mean FEC at D-1
(EPG) (95% CI)
Mean FEC at D+6
(EPG) (95% CI)
ERR (%)
(95% CI)
Mean WC at
D+7 (95% CI)
WRR (%)
(95% CI)
CP45 6 500.0(41.7; 1,200) 5416.7(2200.0; 9233.3) 2.1*(−629.8; 68.9) 976.5(697.3; 1,256.1) −14.0*(−213.7; 36.1)
CP115 6 233.3(16.7; 558.3) 1425.0(183.3; 2908.3) 74.2(−98.1; 96.9) 278.5(64.7; 551.7) 67.5(−3.4; 93.9)
CP225 6 241.7(50.0; 533.5) 808.3(208.3; 1741.7) 85.4(−15.4; 97.1) 160.3(61.3; 265.8) 81.3(43.7; 93.9)
CP450 6 441.7(25.0; 1,150.0) 41.7(0.0; 108.3) 99.2*(93.6; 100) 8.5(2.7; 15.7) 99.0*(97.0; 99.7)
Control 6 308.3(33.3; 733.3) 5533.3(758.3; 11608.3) _ 856.3(328.7; 1,384.0) _
The mean fecal egg counts (FEC) at day (D) -1, mean worm counts (WC) at D+7 and the reduction in WC at D+7 compared to the control group (WCR) for a
single-oral dose of 45, 115, 225, and 450 μmol papaya CPs (P45, P115, P225 and P450).
*pair-wise comparison between CP450 and CP45 revealed a significant difference with p-value <0.01.
-
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Figure 1 The efficacy of four doses of papaya CPs against high intensity T. suis infections assessed by means of egg reduction rate
(black) and worm reduction rate (red). Points represent mean values (n=6) and error bars show 95% CI with inserted values where bars extend
beyond the Y-axis.
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anthelminthic properties that are extremely effective
against Trichuris infections. Here a single-oral dose of
450 μmol of papaya CPs reduced the egg excretion and
worm burden by more than 97%, regardless of the level
of infection intensity. These efficacy results are superior
not only to the efficacy results of a single-oral dose of 400
mg ALB in the current study, but also to most ERR effi-
cacy results reported in human populations for ALB and
MEB, either administered in a single oral dose on one day
(1×1 ALB: 64.5%; 1×1 MEB: 62.7%, Levecke et al., unpub-
lished data), or even in several doses over consecutive days
(2×1 ALB: 73.5%, 2×1 MEB: 87.1% [35], 3×1 ALB: 94.0%,
3×1 MEB: 97.3% [36], a double oral dose on 1 day (1×2
ALB: 94.8%, 1×2 MEB: 90.3% [37]. Single dose CP treat-
ment was also considerably more effective in removing T.
suis than any of the other compounds trialed in recent
years (1× levamisol: 0% [38], 1× ivermectin: 86.8% [38],
1× tribendimidine: 31.1% [11], 1× nitazoxanide: 13.4%
[12]) and drug combinations (1×1 ALB+MEB: 96.1%;
2×1 ALB+MEB: 97.3% [37], 1×1 ALB+ivermectin:
91.1% [38] and 97.5% [39]; ALB+diethylcarbamazine:
79.4% [39]; 2×1 ALB+nitazoxanide: 54.9% [35]; 1×1
MEB+levamisole: 85.0% [40]; 1×1 MEB+ivermectine:
96.7% [38]; pyrantel-oxantel: 86.9% [41].
Despite these promising results, there are some
aspects that still need to be addressed before papaya CP
can be considered as an acceptable alternative anthel-
minthic drug for MDA programs in the control of STH.
These include formulation, dose and safety. At present,
a dose 450 μmol papaya CPs represents a mass of ~45 g,
and this poses an important obstacle in treating both
human patients and animals but particularly a pediatric
population due to the quantity of material. Neverthe-
less, given that the CPs used in the current work were
contained entirely in a solution (unlike in some earlier
work where gel-like latex was used, Stepek et al. [21],
further concentration is possible, and a range of different
vehicles/matrices can be exploited to generate a formula-
tion and delivery system in a smaller volume that is more
acceptable for oral delivery.
The dose–response trial indicated that the dose can be
halved (225 μmol), without losing too much of its efficacy
(~99% vs. ~80%). Although this reduction in dose will also
half the mass of CP, it still remains substantial (~22 g) and
in terms of weight and bulk, more than alternative, albeit
less effective, treatments.
‘Papain’ has found various applications in the daily life
of people and in the food industry, and is therefore
widely available for these purposes, with less regulation
than conventional medicines. However, the amounts of
papain used by the consumer for these tasks are clearly
much lower than the minimal dose that showed anthel-
mintic efficacy against trichuriasis in our trials (115 μmol
or ~11 g). Some side effects of papaya CPs have been
reported previously in animals and humans but these
are relatively scarce. In the sheep trials reported by
Buttle et al. [27], some oral blistering was observed, but
this was not serious at the doses used [27]. Regurgitation
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Figure 2 Scatterplots describing the fecal egg counts as a function of the worm counts.
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of CP and their subsequent inhalation present a more
serious threat, but again when administered to animals by
well-trained staff oral delivery to mice did not result in
losses. Novel formulations based on syrups would also
most-likely eliminate this as a problem in treatment of
people. CPs are proteins and there is also the risk of
allergy developing to their frequent application. However,
it should be emphasized here that the side effects have
only been evaluated poorly to date and that this is one
aspect of the use of papaya CPs that will have to be more
thoroughly investigated before they can be marketed as
anthelmintics.
The poor efficacy of ALB against T. suis (ERR: 59.0-64.4;
WRR: 23.2-39.0) was not entirely unexpected, as the ERR
results resemble those reported in a recent meta-analysis
including five trials assessing the efficacy of a single oral-
dose of 400 mg ALB in school children Cameroon,
Ethiopia, Tanzania and Vietnam (ERR: 64.5% [95% CI:
44.4; 84.7]; Levecke et al., unpublished data). Although
our results confirm the usefulness of pigs as a model for
assessing drug efficacy against trichuriasis, we expected a
more pronounced difference in efficacy across the two
levels of infection intensity. The ERR for ALB against
trichuriasis in the five aforementioned trials with school
children ranged from 29.3% for a mean FEC at baseline of
1193 EPG, to 92.4% for a mean FEC at baseline of 420
EPG. In the current study, ALB provided comparable ERR
results against low (mean FEC = 492 EPG, ERR = 64.4%)
and heavy-intensity infections (mean FEC = 9267 EPG,
ERR = 59.0%). Only for WRR was there a pronounced
difference in efficacy (low: 23.2% vs. heavy: 39.0%).
Finally, our results indicate that egg excretion in-
creased as a function of worm burden, suggesting that
FEC are a valid proxy of worm burden for trichuriasis
in pigs.
Conclusions
A single dose of 450 μmol papaya CPs provided greater
efficacy against T. suis infections in pigs than a single-
oral dose of 400 mg ALB. Although these results high-
light the possibility of papaya CPs being used to treat
human trichuriasis further development is needed in
order to obtain and validate an oral formulation for
use in both human and veterinary medicine. Our results
confirm the suitability of pigs as a model for assessing
drug efficacy against trichuriasis. Finally, this study sug-
gests that FEC are a valid proxy for worm burdens in this
host-parasite system.
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